|
![]() |
|
|
Lomustine: profile and news
Zanosar® Superior to Doxorubicin for Advanced Carcinoid Tumors Aug 2, 2005 New Regimen Effective for Relapsed Non-Hodgkin’s Lymphoma Jul 18, 2005 Clinical Data Presented at SNM Annual Meeting Demonstrates Both ... Jun 21, 2005 Clinical Data Presented at SNM Annual Meeting Demonstrates Both ... Jun 21, 2005 New Regimen Effective For Refractory non-Hodgkin's Lymphoma Jun 3, 2005 Other information Indication For use as a single agent in addition to other treatment modalities to treat brain tumors and Hodgkin's disease Pharmacology Although it is generally agreed that CeeNU alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Mechanism Of Action Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents Drug Category Antineoplastic Agents; ATC:L01AD02 Brand Names/Synonyms Belustine; CCNU; CCRIS 860; CHEMBANK4359; Ccnu [Chloroethyl Nitrosoureas]; Cecenu; Ceenu; Ceenu®; Chloroethylcyclohexylnitrosourea; Cinu; Cyclohexyl Chloroethyl Nitrosourea; HSDB 6519; ICIG 1109; Lomustina [Inn-Spanish]; Lomustine; Lomustine [Usan:Ban:Inn]; Lomustinum [Inn-Latin]; RB 1509; SRI 2200; [Inn-Spanish] Dosage Forms CAPSULES Absorption Rapidly and completely absorbed (in 30-60 minutes) Interactions Interactions for Lomustine: No Information Provided. Chemical IUPAC Name 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea Chemical Formula C9H16ClN3O2 Half Life 16 hours-2 days Drug Type Approved Drug # Accession No APRD00292 CAS Registry Number 13010-47-4 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |